Neurolite
- Generic Name: bicisate dihydrochloride kit
- Brand Name: Neurolite
Neurolite (Bicisate Dihydrochloride Kit) side effects drug center
Neurolite Side Effects Center
What Is Neurolite?
Neurolite (bicisate dihydrochloride kit) single photon emission computerized tomography (SPECT) is a diagnostic radiopharmaceutical indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed.
What Are Side Effects of Neurolite?
Side effects of Neurolite include:
- headache,
- dizziness,
- seizure,
- agitation,
- anxiety,
- feeling unwell (malaise),
- drowsiness,
- problems with smell,
- hallucinations,
- rash,
- nausea,
- lightheadedness/fainting,
- cardiac failure,
- high blood pressure (hypertension),
- chest pain (angina),
- interruptions in breathing (apnea), and
- bluish discoloration of skin due to low oxygen levels (cyanosis)
Dosage for Neurolite
The recommended dose range of Neurolite for intravenous administration for a 70 kg patient is 370-1110 MBq (10-30mCi).
Neurolite In Children
Safety and effectiveness of Neurolite in the pediatric population has not been established.
What Drugs, Substances, or Supplements Interact with Neurolite?
Neurolite may interact with other medicines.
Tell your doctor all medications and supplements you use.
Neurolite During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Neurolite; it is unknown if it would harm a fetus. of Neurolite can pass into breast milk. Formula should be substituted for breast milk until the technetium has cleared from the body of the breastfeeding woman.
Additional Information
Our Neurolite (bicisate dihydrochloride kit) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Neurolite Professional Information
SIDE EFFECTS
In clinical trials, Neurolite has been administered to 1063 subjects (255 normals, 808 patients). Of these, 566 (53%) were men and 494 (47%) were women. The mean age was 58 years (range 17 to 92 years). In the 808 patients, who had experienced neurologic events, there were 11 (1.4%) deaths, none of which were clearly attributed to Neurolite.
A total of 60 subjects experienced adverse reactions; the adverse reaction rates were comparable in the <65 year, and the >65 year age groups.
The following adverse effects were observed in ≤ 1% of the subjects: headache, dizziness, seizure, agitation/anxiety, malaise/somnolence, parosmia, hallucinations, rash, nausea, syncope, cardiac failure, hypertension, angina, and apnea/cyanosis.
In clinical trials of 197 patients, there were inconsistent changes in the serum calcium and phosphate levels. The cause of the changes has not been identified and their frequency and magnitude have not been clearly characterized. None of the changes required medical intervention.
Read the entire FDA prescribing information for Neurolite (Bicisate Dihydrochloride Kit)
&Copy; Neurolite Patient Information is supplied by Cerner Multum, Inc. and Neurolite Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.